NCT03792750View on ClinicalTrials.gov

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2018

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
Advanced Cancer
Interventions
DRUG

BMS-986205

Specified Dose on Specified Day

BIOLOGICAL

Nivolumab

Specified Dose on Specified Day

Trial Locations (1)

310016

Local Institution, Hangzhou

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY